The US FDA has withdrawn approval of the breast cancer indication for bevacizumab [Avastin]

Source: Reactions Weekly, Volume 1, Number 1379, 2011-11-26 , pp. 2-2(1)

Publisher: Adis International

Keywords: Bevacizumab, adverse reactions; Bevacizumab, therapeutic use; Breast-cancer, treatment; Development-status; Food-and-Drug-Administration; Healthcare-news; Market-withdrawal; Pharmacovigilance

Document Type: Short communication

Publication date: 2011-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers